Authors' reply to: "Preventing Atrial Fibrillation with SGLT2 Inhibitors: Time, Sex, and Substrate" by Karakasis et al [0.03%]
对Karakasis等关于“使用SGLT2抑制剂预防房颤：时间、性别和基质”的作者回信
Damiano Fedele,Sara Amicone,Lisa Canton et al.
Damiano Fedele et al.
Seeking for the Boundaries of De-escalation in Antiplatelet Therapy for Acute Coronary Syndromes [0.03%]
急性冠脉综合征抗血小板治疗减停的边界探索
Mattia Galli,Felice Gragnano,Marco Valgimigli
Mattia Galli
Witnessing a Possible Revolution in Antiplatelet Therapy for Coronary Artery Bypass Grafting [0.03%]
冠脉旁路移植术抗血小板治疗的可能革命见证
Mattia Galli,Felice Gragnano,Mario Gaudino
Mattia Galli
An Old Drug in a New Era: Digitoxin in the Spotlight After DIGIT-HF [0.03%]
DIGIT-HF后登心酮研究新进展：老药新用显成效
Felice Gragnano,Mattia Galli,Paolo Calabrò et al.
Felice Gragnano et al.
Diuretic strategies in acute heart failure: a systematic review and network meta-analysis of randomized clinical trials [0.03%]
急性心力衰竭利尿剂策略的系统评价和网状Meta分析
A Cannatà,G Anastasia,V De Marzo et al.
A Cannatà et al.
Aims: Several diuretic strategies, including furosemide iv boluses (FB) or continuous infusion (FC), are used in acute heart failure (AHF). Methods and re...
Preventing Atrial Fibrillation with SGLT2 Inhibitors: Time, Sex, and Substrate [0.03%]
钠葡萄糖共转运蛋白2抑制剂预防房颤的时间、性别和基底因素
Paschalis Karakasis,Antonios P Antoniadis,Nikolaos Fragakis
Paschalis Karakasis
Long-term effectiveness of ACE inhibitors or angiotensin receptor blockers in myocardial infarction with preserved left ventricular ejection fraction [0.03%]
心功能保留的心肌梗死后使用ACE抑制剂或ARB的长期疗效
Anna B C Humphreys,Bertil Lindahl,Anita Berglund et al.
Anna B C Humphreys et al.
Aims: Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) are effective in the long-term treatment of myocardial infarction with reduced left ventricular ejection fraction (LVEF). Howev...
Clinical features modifying the cardiovascular benefits of GLP-1 receptor agonists: a systematic review and meta-analysis [0.03%]
GLP-1受体激动剂心血管获益的影响因素：系统评价和.meta.分析
Arzu Kalayci,James Louis Januzzi,Makiko Mitsunami et al.
Arzu Kalayci et al.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D), but heterogeneity exists across cardiovascular outcome trials (CVOTs). A comprehensive search of...
Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease [0.03%]
房颤和外周动脉疾病患者中利伐沙班与阿哌沙班的有效性及安全性比较研究
Loubna Dari,Sarah Beradid,Joël Constans et al.
Loubna Dari et al.
Aims: To assess whether rivaroxaban is associated with a decreased risk of major adverse limb events (MALE), stroke, systemic embolism (SE), and major bleeding (MB) among patients with non-valvular atrial fibrillation (NV...
Impact of early in-hospital initiation of sacubitril/valsartan on left ventricular reverse remodelling in acute heart failure [0.03%]
早期院内使用沙库巴曲缬沙坦对急性心力衰竭患者左室逆重构的影响
Tomonori Takahashi,Kenya Kusunose,Takumi Imai et al.
Tomonori Takahashi et al.
Aims: The effect of initiating sacubitril/valsartan (Sac/Val) therapy during hospitalization for acute heart failure (AHF) on left ventricular (LV) remodelling remains unclear. This study aimed to assess the impact of Sac...